OTR Acquisition Corp. (NASDAQ:ORTA) filed an 8-K this afternoon with the results of its shareholders vote to approve its combination with biotech firm Comera Life Sciences in a special meeting held on Tuesday.
The business combination was overwhelmingly approved as it saw 9,675,143 votes in favor of the transaction and just 177,849 against it. But, today’s 8-K filing disclosed that holders of an aggregate of 10,279,363 shares of ORTA exercised their right to redeem their shares, removing 98.392% of the SPAC’s trust.
The parties did not disclose an exact timeline for the closing of the business combination, but it is expected to be completed shortly. Following the closing, the combined company is expected to trade on the Nasdaq.
OTR initially announced its $151.3 million combination with Comera on January 31, 2022. The Woburn, Massachusetts-based company utilizes formulation science and technology to transform essential biologic medicine from IV to subcutaneous forms.
The company’s stockholders also approved the Charter Amendment Proposal and the Equity Incentive Award Plan Proposal during Tuesday’s special meeting.
ADVISORS
- Maxim Group LLC served as sole financial and capital markets advisor to Comera in connection with the business combination agreement.
- Loeb & Loeb LLP is serving as legal counsel for Comera, and Greenberg Traurig LLP is serving as legal counsel for OTR
McKinley Acquisition Corporation (NASDAQ:MKLYU) has filed for a $150 million SPAC to hunt for an innovative target company with an experienced financial team that has dabbled in SPACs before. The new SPAC is offering investors one right to a 1/10 share in each unit with no overfunding of the trust, but it could provide a...
At the SPAC of Dawn The rain of SPACs has continued with four expected to make their debuts during today’s trading sessions after pricing their IPOs overnight. The largest of these, EQV Ventures II (NASDAQ:EVACU), even managed an upsize, making it the largest SPAC IPO since Ares II (NYSE:AACT) pulled together $450 million in 2023....
EQV Ventures II (NASDAQ:EVACU) announced the pricing of its upsized $420 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “EVACU”, Wednesday, July 2, 2025. The new SPAC plans to merge with an energy target involved in upstream exploration or production. EQV II’s management team is led by...
Vendome Acquisition Corporation I (NASDAQ:VNMEU) announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “VNMEU”, Wednesday, July 2, 2025. The new SPAC plans to focus its search on target business in the consumer sector operating in North America, Southeast Asia, and Europe....
Origin Investment Corp. I (NASDAQ:ORIQU) announced the pricing of its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ORIQU”, Wednesday, July 2, 2025. The new SPAC aims to mount a broad search for a target with a strong management and both revenue and earnings growth potential....